malathion

Trade name: ovide

Small moleculeapproved

Approved

Aug 2, 1982

Malathion is an organophosphate insecticide, an inhibitor of cholinesterase. In low doses (0.5%) malathion is used for treatment of pediculosis and scabies. — NCATS

Clinical trial activity

9 trials · 4 clinical orgs · 5 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Feb 1, 2004 (NCT00819520)

Timeline

1980s

Aug 2, 1982
GenDerm — Earliest FDA Approval
Aug 2, 1982
GenDerm — NDA Organization
Aug 2, 1982
Taro Pharmaceuticals — NDA Secondary Org
Aug 2, 1982
Taro Pharmaceuticals — Marketing Organization

2000s

Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
Jan 1, 2006
Taro Pharmaceuticals — Earliest Phase 2 Sponsor(trial)
Jan 1, 2009
Taro Pharmaceuticals — Earliest Phase 1 Sponsor(trial)
Mar 6, 2009
Mylan — Marketing Organization
Mar 6, 2009
PHARMOBEDIENT — Marketing Organization

2010s

May 23, 2012
Suven Life Sciences Limited — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Acetylcholinesterase 1ANTAGONIST
ace-1 antagonist
- Acetylcholinesterase 1 (ace-1) ↗

Approval history

approvedAug 2, 1982

Chemistry & pharmacology

Loading structure…

SMILES

CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC

Mol. weight: 330.358 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Topical
Availability: Prescription Only

Oral

Parenteral

Topical

Yes

Sources

Also known as

carbetovur
carbetox
carbofos
carbophos
carbophos
carbophos
cimexan
cythion
cythion
derbac-m
derbac-m
diethyl (dimethoxyphosphinothioylthio)succinate
diethyl (dimethoxyphosphinothioylthio)succinate
[(dimethoxyphosphinothioyl)thio]butanedioic acid diethyl ester
[(dimethoxyphosphinothioyl)thio]butanedioic acid diethyl ester
ethiolacar
karbofos
karbofos
malathine
malathion
malathion
malathion
malathion
malathion
malathion
malathion
malathion
malathion
malathion
malathion
malathyne
maldison
maldison
mercaptothion
mercaptothion
o,o-dimethyldithiophosphate diethylmercaptosuccinate
o,o-dimethyldithiophosphate diethylmercaptosuccinate
o,o-dimethyl s-(1,2-bis(ethoxycarbonyl)ethyl)
o,o-dimethyl s-(1,2-bis(ethoxycarbonyl)ethyl)
o,o-dimethyl s-(1,2-dicarbethoxyethyl) dithiophosphate
o,o-dimethyl s-(1,2-dicarbethoxyethyl) dithiophosphate
o,o-dimethyl s-(1,2-dicarbethoxyethyl)phosphorodithioate
o,o-dimethyl s-(1,2-dicarbethoxyethyl)phosphorodithioate
o,o-dimethyl s-1,2-di(ethoxycarbamyl)ethyl
o,o-dimethyl s-1,2-di(ethoxycarbamyl)ethyl
organoderm
organoderm
ovide
ovide
ovide
prioderm
prioderm
sadofos
suleo-m
suleo-m

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03236168	Phase 3	Aug 1, 2017	University of London
NCT00927472	Phase 3	Aug 1, 2009	Taro Pharmaceuticals
NCT00963508	Phase 3	Aug 1, 2009	Taro Pharmaceuticals
NCT00927407	Phase 1	Jul 1, 2009	Taro Pharmaceuticals
NCT02213055	Phase 2	May 1, 2009	Rutgers University
NCT00752973	Phase 2/Phase 3 (Phase 3)	Sep 1, 2008	Taro Pharmaceuticals
NCT00291057	Phase 2	Feb 1, 2006	Taro Pharmaceuticals
NCT00244439	Phase 3	Dec 1, 2005	Taro Pharmaceuticals
NCT00819520	Phase 3	Feb 1, 2004	Johnson and Johnson

Showing 9 of 9 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Taro Pharmaceuticals	For profit	6	6	3	2005
Johnson and Johnson	For profit	1	1	1	2004
Rutgers University	Academic/Hospital	1	1	1	2009
University of London	Academic/Hospital	1	1	1	2017

4 organizations

Page 1 / 1

Marketing (7)

Organization	Org type	Relationship	Date
GenDerm	For profit	NDA	Aug 2, 1982
Mylan	For profit	MKTG	Mar 6, 2009
PHARMOBEDIENT	For profit	MKTG	Mar 6, 2009
Suven Life Sciences Limited	For profit	SYN	May 23, 2012
Suven Life Sciences Limited	For profit	MKTG	May 23, 2012
Taro Pharmaceuticals	For profit	NDA2	Aug 2, 1982
Taro Pharmaceuticals	For profit	MKTG	Aug 2, 1982